SNIPR BIOME ApS (“SNIPR” or “the Company”), a clinical stage biotech company pioneering CRISPR-based therapies, today announces grant of patent EP4392563B on February 24th 2025 by the European Patent ...

This is exemplified by granted US patent US11,517,582, which covers the use of CRISPR-Cas systems to achieve selective killing of bacteria by at least 1000-fold in situations where bacteria are ...

Call for Papers! Cas12-mediated Genome Editing in Plants . Ca. 01. Time Schedule . Submission deadline: Sunday, 30th November ...

Wandera KG, Schmelz S, Migur A, Kibe A, Lukat P, Achmedov T, Caliskan N, Blankenfeldt W, Beisel CL: AcrVIB1 inhibits CRISPR-Cas13b immunity by promoting unproductive crRNA binding accessible to RNase ...

The ability to control gene expression across a wide range is crucial for many fields, including bioengineering, disease ...

CRISPR-Cas systems are prokaryotic immune systems that confer resistance to foreign genetic elements such as plasmids and phages. CRISPR-Cas systems have been exploited for targeted genome editing.

Traditional diagnostic methods, such as bacterial culture and PCR-based testing, can take 24–72 hours, delaying critical ...

CRISPR-based Spotlight Therapeutics has shut down, former CEO Mary Haak-Frendscho, Ph.D., confirmed with Fierce Biotech. | CRISPR-based Spotlight Therapeutics has shut down, former CEO Mary ...

The CRISPR-Cas9 system offers groundbreaking genome editing capabilities, yet off-target cleavage raises concerns about genetic safety and efficacy.